Many patients rule themselves out before a clinic ever does. That instinct is understandable, especially when age is discussed so bluntly in fertility care. But age alone does not tell the full story of whether treatment with your own eggs is still worth pursuing.
Age has the biggest effect on embryo genetics. Under 35 years old, about 70% of embryos generated are genetically normal. Between 38 and 40 years old, about 30% of embryos are euploid. Between 41 and 43 years old, only 10% of embryos are genetically normal. By age 44, the chance of a euploid embryo is less than 10%, and at 46 to 49 years old, the euploidy rate is zero.
Those numbers explain why timing becomes urgent after 38. If you are over 38 and want to try with your own eggs, delaying treatment can mean losing ground quickly. A woman may still ovulate, still have periods, and still produce eggs, but the odds that an embryo will be genetically normal fall sharply with time.
Online success stories can distort that reality. Pregnancies after 45 may look more common on social media than they are statistically. Some people do not disclose that they used egg donation, and some may have frozen eggs when they were younger. Rare success with a genetically normal embryo at 45 can happen, but it remains rare, and even then, the embryo may still fail to develop or end in miscarriage.
An effective IVF plan after 38 begins with a detailed assessment rather than a standard protocol. Two women of the same age can have very different chances depending on ovarian reserve and hormone profile. A 38-year-old with AMH 1 should not be treated the same way as a 38-year-old with AMH 2 Ng/mL.
The basic workup should include:
The antral follicle count is measured with a transvaginal scan. Cycle monitoring also includes FSH and LH on day 3 of the cycle, while AMH, prolactin, and thyroid testing are cycle-independent. If FSH remains above 16 for 6 months in a row, that points toward egg donation.
This is where individualised care becomes most important. AMH is a rough guide to how strongly the ovaries may respond to stimulation. In this setting, an AMH above 2 Ng/mL is considered a good ovarian reserve. Very low AMH may mean there is little or no ovarian response. That does not answer every question, but it helps determine whether one cycle is likely to be enough or whether a patient may need a more staged plan.
Patients often focus on how many eggs can be retrieved. Clinics do too, because egg number affects what comes next. But after 38, the real target is not simply collecting eggs. It is creating enough blastocysts to have a realistic chance of finding a normal embryo.
With controlled ovarian hyperstimulation using a middle dose of hormones, a 38-year-old with AMH above 2 Ng/mL may produce 15 to 20 eggs. After ICSI and culture to day 5, about half of the 15 eggs may develop to blastocysts, resulting in 6 or 7 blastocysts. After genetic testing, 20% to 30% of embryos may be healthy.
The math becomes much less forgiving when fewer embryos are available. At age 36, the euploidy rate is 60%. At age 38, it is only 20%. If a 36-year-old has 6 blastocysts, statistically, 3 should be healthy. If the same patient is 38 years old with 6 blastocysts, only 1 or 2 would statistically be healthy.
This is also why “I got eggs” and “I have a real chance” are not the same thing. A cycle can look productive early on and still end with no transferable embryo. For patients with lower reserve, the question quickly becomes whether they can build enough embryos across more than one cycle to make testing and transfer worthwhile.
If AMH is around 1, one cycle may not generate 6 blastocysts. In that situation, embryo banking may be the strategy that keeps treatment realistic. The idea is simple: do one cycle, test and freeze the embryos, wait 2 to 3 months for recovery, then do another cycle.
That waiting period matters because ovarian response may be low one month after egg retrieval, and AMH drops after each cycle. Spacing cycles by 2 to 3 months is meant to give the body time to recover before trying again.
For some patients, this approach can turn a weak single cycle into a more serious cumulative attempt. If one blastocyst is created, treatment can be repeated every two or three months. But there is also a point where the process stops making sense. If there is no blastocyst from those two or three eggs, treatment should be abandoned.
For some patients, that may be a hard message to hear, but it can be kinder than continuing cycle after cycle without a realistic path to pregnancy.
For patients who still hope but want scientific evidence on paper, PGT-A can clarify what is happening. In practical terms, testing helps answer a painful but essential question: are you making embryos that can plausibly become a pregnancy with a heartbeat?
That question becomes especially important after repeated miscarriage or repeated failed IVF. If an embryo does not have a heartbeat, the cause may be a genetic abnormality or an immune system that is rejecting the embryo. Genetically abnormal embryos may progress to five or six weeks, the gestational sac may be seen, and then the heartbeat stops.
That is why testing can be useful after losses. It separates the problem of making embryos from the problem of sustaining a pregnancy. Before another transfer, a patient needs to know whether she can generate healthy embryos and whether there is a real chance of achieving a heartbeat.
Testing also helps frame expectations. If a patient has one euploid embryo, the chance of success after one transfer is 70%. If a patient has 3 euploid embryos, the chance of success is 90%. If there are no embryos, all embryos are genetically abnormal, or there are zero eggs, the chance is zero.
Once embryos have been tested, the next decision is how to transfer them. That is why a frozen transfer strategy is often preferred in this age group.
A well-timed transfer can mean the difference between placing an embryo into the best possible environment and transferring it at the wrong moment.
Not every failed transfer is about embryo quality. Sometimes the problem is mechanical, and one of the clearest examples is hydrosalpinx.
If a patient has hydrosalpinx in both tubes and embryos available, the tubes should be removed by laparoscopic bilateral salpingectomy before transfer. The reason is straightforward: fluid from a damaged tube can drain toward the embryo, and the embryo may not tolerate it.
This is one of those situations where proceeding directly to transfer can undermine the rest of the IVF process. Even if a patient already has embryos, the tubes may still need to be dealt with first.
There is no single emotional moment when someone becomes ready to hear about egg donation. Medically, though, the numbers narrow the options. At age 44, the chance of a euploid embryo is less than 10%. At 46 to 49 years old, the euploidy rate is zero.
Not every patient accepts that shift immediately. Some want one more attempt with their own eggs. Some want testing to confirm what the numbers suggest. Some need to see abnormal embryo results on paper before moving on. Coming to terms with that decision is deeply personal.
Still, there are situations where the answer becomes blunt. If a cycle failed because there were no eggs, that is the end of the story. If the eggs did not fertilise, that is also the end of the story. If embryos were generated, then their genetics need to be checked. The point is not to take hope away. It is to direct hope toward the option that still has a chance.
IVF after 38 is not a one-protocol field.
That kind of adjustment is exactly why blanket statements about age can be unhelpful. Some patients are poor candidates for more treatment. Others are not being offered the most thoughtful version of it.
For patients looking abroad, legal limits shape what clinics can offer. Beyond that, there can be problems with the Ministry of Health, including fines or loss of license for the doctor or clinic.
That legal framework matters because it sets the outer boundary of what is possible, even when a patient still wants to continue. It does not change the biology of egg quality, but it does affect where and how treatment can happen.
IVF after 38 is not hopeless, but it is unforgiving of delay, vague plans, and false reassurance. The central question is whether you can still make a genetically normal embryo, and the answer depends on both age and ovarian reserve. Tests such as AMH, antral follicle count, FSH, and embryo genetics help turn that question from guesswork into strategy.
For some women, that strategy will be a fast treatment with their own eggs. For others, it will be embryo banking, frozen transfer after PGT-A, or surgery before transfer if hydrosalpinx is present. And for some, the most realistic next step will be egg donation. The goal is to identify as early as possible which path still offers a real chance.
Some of these cases are explained by egg donation, which people may not disclose. Others may involve eggs that were frozen at a younger age but are not mentioned. After 44 years old, the euploidy rate is less than 10%, so there are not many 44- or 45-year-olds who will have the chance of a golden egg and one genetically normal embryo. In rare cases, a woman may have one genetically normal embryo at age 45, but the embryo may still fail to develop or result in miscarriage.
The key issue is hydrosalpinx or hematosalpinx: fluid in the tube, either transparent liquid that could be infectious or blood in the tube. If an embryo is transferred to the womb while such a tube remains in place, the liquid can drip toward the embryo, and the embryo may not tolerate it. According to the American law school of medicine, tubes with Hydrosalpinx or hematosalpinx must be removed before transfer. Even if there is hydrosalpinx in both tubes and 5 embryos, the tubes should still be removed.
Yes, but the first question is whether the embryos are genetically normal. If an embryo does not have a heartbeat, it may be genetically abnormal or rejected by the immune system. PGT-A/PGDA is needed to know whether good, healthy embryos are being generated and whether there is a chance of a heartbeat. At age 42, if there are no genetically normal embryos, there will be no heartbeat. Genetically abnormal embryos may reach five or six weeks, the gestational sac may be visible, and then the heartbeat stops. This usually indicates a problem with the embryo or with immunology.
At age 44, the chance of a euploid embryo is less than 10%. Egg donation is the recommended path straight away, as 10% is too low for a PGT-A cycle. If you still want scientific evidence on paper, we can proceed with PGT-A. If testing shows the embryo is genetically abnormal, or if fertilisation fails and no embryos develop, egg donation is needed.
It depends very much on age and on whether a blastocyst is generated. A young patient may succeed with very few eggs: one example was a 23-year-old Latin American woman with 3 eggs, 1 euploid embryo, and a son. At 23, the euploidy rate was described as 80% out of 3 eggs. At 40, if there are only 3 eggs, there may be 1 healthy embryo or none. If one beautiful blastocyst is created, embryo banking can be repeated every 2 or 3 months. If there is no blastocyst, treatment should be stopped. The situation is very personal.
Start with blood work and a scan. If FSH is more than 20, menopause is probably slowly starting. To have periods, HRT is probably needed. One option is a daily mixture of estrogens and progesterone, like a birth control pill, which produces no period but may make you feel better. Another option is sequential HRT: 15 days of estrogens and 5 days of progesterone, then stopping the medication to trigger a period. The cheapest first step is to check FSH, because an ultrasound costs money and FSH gives a clearer idea of what is happening.
This needs a proper review, not a superficial answer. The key details are age and the reason the cycles failed. If a cycle failed because there were no eggs, that ends the story. If the cycle failed because the eggs did not fertilise, that also ends the story. If embryos were generated, their genetics must be checked. A professional consultation is needed to assess the case properly.
PCOS patients can be challenging. At age 49, eggs may still be produced, but fewer than 10% will be genetically normal. If you want to try, that can be supported, but you are slowly becoming a candidate for egg donation. Treatment in this country (Spain) is possible until age 52.
At 48, the practical next step is usually a first consultation about egg donation and how to find a donor who looks like you. The goal is for the child to appear genetically related to you. It is easier to have a case from egg donation before age 50 than after 50.
The clinic treats patients until age 52. Beyond that, there can be problems with the Ministry of Health, including fines or loss of license for the doctor or clinic. Some countries such as Greece or Cyprus may allow treatment until 55 and may allow surrogacy, but not every option is available in Spain.
Do not change the winning protocol. If one cycle produced three blastocysts and another produced zero, keep the protocol that worked. With uneven follicle growth, start with a birth control pill or a mixture of estrogen and progesterone to synchronise the eggs, which usually takes 10 to 14 days. Then induce the period and restart stimulation with the same good combination of Gonal-f and Myofert, with Citrotide as used before. The aim is three or four blastocysts, then check their euploidy. The protocol with Trecovell, or whatever was used in the zero-blastocyst cycle, did not seem to work.
